Leading the way to safer medication
 Crosscheck  Recommender

Benralizumab

Description

Benralizumab is an anti-eosinophil, humanised afucosylated, monoclonal antibody (IgG1, kappa) that binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα) with high affinity and specificity. The IL-5 receptor is specifically expressed on the surface of eosinophils and basophils. The absence of fucose in the Fc domain of benralizumab results in high affinity for FcɣRIII receptors on immune effectors cells such as natural killer (NK) cells. This leads to apoptosis of eosinophils and basophils through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), which reduces eosinophilic inflammation.

ATC Classification

Code
Title
Category
R03DX10
Benralizumab
R Respiratory system → R03 Drugs for obstructive airway diseases → R03D Other systemic drugs for obstructive airway diseases → R03DX Other systemic drugs for obstructive airway diseases

Trade names

Trade name
Countries

Australia Austria Canada Cyprus Netherlands

Product Monographs

Monograph
Type
Country
FASENRA Solution for injection
MPI, EU: SmPC